Astrazeneca Might Receive Emergency Use Authorization for Its Coronavirus Vaccine — in October: Report | Eastern North Carolina Now

Publisher's note: This post appears here courtesy of the The Daily Wire, and written by Joseph Curl.

    Pharmaceutical company AstraZeneca might be granted an emergency use authorization by the Food and Drug Administration (FDA) for a COVID-19 vaccine, according to a new report.

    The vaccine, being developed by AstraZeneca and Oxford University, could receive authorization as early as October, the Financial Times (FT) reported.

    "The Trump administration is considering bypassing normal US regulatory standards to fast-track an experimental coronavirus vaccine from the UK for use in America ahead of the presidential election, according to three people briefed on the plan," FT reported. "One option being explored to speed up the availability of a vaccine would involve the US Food and Drug Administration awarding "emergency use authorisation" (EUA) in October to a vaccine being developed in a partnership between AstraZeneca and Oxford university, based on the results from a relatively small UK study if it is successful, the people said."

    But Fortune reported that "AstraZeneca says it has held no discussions with the U.S. government about emergency authorization for the COVID-19 vaccine it is manufacturing."

  • That vaccine is still undergoing late stage human clinical trials in several sites around the world, including in the U.K. and the U.S., making a rapid approval under the criteria the U.S. Food and Drug Administration has established so far a long shot.

    Other vaccines are in the testing stage, as well. The world's largest COVID-19 vaccine study in the world began early this month, with the first of 30,000 Americans volunteering to take the shots. The experimental vaccine, developed by the National Institutes of Health (NIH) and Moderna Inc., is in phase three of the development process, which includes tests at clinical sites across the country.

    "Having a safe and effective vaccine distributed by the end of 2020 is a stretch goal, but it's the right goal for the American people," NIH Director Dr. Francis Collins said in a statement. "The launch of this phase-3 trial in record time while maintaining the most stringent safety measures demonstrates American ingenuity at its best and what can be done when stakeholders come together with unassailable objectivity toward a common goal."

    Meanwhile, Russia said last week that it had approved a vaccine for COVID-19, becoming the first nation in the world to mark the achievement.

    President Vladimir Putin, who announced the approval of the vaccine, said one of his two adult daughters has already been inoculated. Putin also said the vaccine underwent all tests to show its effectiveness, although Russian officials offered no data to back up his claim. The approval was granted by Russian health officials after just two months of human testing, Reuters reported.

    "A vaccine against coronavirus has been registered for the first time in the world this morning. I know that it works quite effectively, it forms a stable immunity," Putin said on state TV. "I repeat, it has passed all the needed checks. ... We must be grateful to those who made that first step very important for our country and the entire world."

    But scientists warned that the vaccine never underwent Phase 3 trials, which involve thousands of patients and usually lasts for months.

    "Fast-tracked approval will not make Russia the leader in the (vaccine) race, it will just expose consumers of the vaccine to unnecessary danger," Russia's Association of Clinical Trials Organizations said Monday, urging government officials to postpone clearing the vaccine without completed advanced trials.
Go Back


Leave a Guest Comment

Your Name or Alias
Your Email Address ( your email address will not be published)
Enter Your Comment ( no code or urls allowed, text only please )




Kim Jong Un’s Sister May Be Even Worse Dictator Than Her Brother, Experts Warn Guest Editorial, Editorials, Op-Ed & Politics Jerry Falwell Jr. Reportedly Withdrew Resignation After Media Reported It


HbAD0

Latest Op-Ed & Politics

President Joe Biden took direct aim at Supreme Court Justice Clarence Thomas during a recent interview, referring to him simply as “the guy who likes to spend a lot of time on yachts.”
The best way the county and city can help hold down inflation is to resist all tax increases
Pope Francis lambasted leftist gender ideology during an address this week, warning that it presented an extreme danger to mankind.
amnesty would just encourage more illegal aliens to storm our borders
The Christmas candy was barely off the shelves when the Valentine’s candy appeared. Red and pink hearts with caramel and nut-filled chocolate goodness caught our eye. We are reminded of how we love love. Young love, especially.
far left sugar daddy has also funded anti-Israel groups and politicians in US
Be careful what you wish for, you may get it
America needs to wake up and get its priorities right

HbAD1

Former President Donald Trump suggested this week that if he becomes president again, he might allow Prince Harry to be deported.
It's a New Year, which means it's time to make resolutions — even for prominent evangelical leaders. The Babylon Bee asked the following well-known figures in the faith what they hope to accomplish in 2024:
Vice President Kamala Harris will visit a Minnesota Planned Parenthood clinic, reportedly the first time a president or vice president has visited an abortion facility.
An eight-mile stretch of the Blue Ridge Parkway near Asheville has been temporarily closed due to a string of “human and bear interactions,” the National Parks Service announced.
University of Wisconsin tried to punish conservatives for the fact that liberals regularly commit crimes to silence opposition
most voters think EU officials not doing a good job on illegal immigration
Come from behind by GOP candidate is a blueprint to 2024
Biden spending and energy policies to blame

HbAD2

 
Back to Top